Research
Hormonal
Circulating very-long-chain saturated fatty acids (VLCSFAs) in plasma are associated with favorable cardiovascular risk markers, including higher HDL-C, lower triglycerides, and higher adiponectin.
Higher levels of specific saturated fatty acids in the blood are linked to better cholesterol profiles (higher HDL, lower triglycerides) and lower inflammation. This suggests these fatty acids may play a role in metabolic health, distinct from other types of saturated fats.
GoodSupportsHIGH confidence
Plasma VLCSFAs were correlated with favorable profiles of blood lipids, C-reactive protein, and adiponectin in the NHS and HPFS and with fasting insulin and C-peptide levels in a nationally representative US comparison population.
Why this rating
Consistent cross-sectional correlations across multiple cohorts and a national survey (NHANES).
Source
Circulating Very-Long-Chain Saturated Fatty Acids and Incident Coronary Heart Disease in US Men and Women
Vasanti Malik et al. · Circulation · 2015
DOI 10.1161/circulationaha.114.014911
cohort · n=2027Cited 92×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher circulating levels of plasma very-long-chain saturated fatty acids (VLCSFAs: C20:0, C22:0, C24:0) are associated with a significantly lower risk of incident coronary heart disease (CHD) in US men and women.Good
- Circulating very-long-chain saturated fatty acids (VLCSFAs) in erythrocytes are NOT significantly associated with a reduced risk of incident coronary heart disease (CHD) after multivariate adjustment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →